fulvestrant

Type: Keyphrase
Name: fulvestrant
First reported Jul 25 2014 - Updated Jul 25 2014 - 1 reports

Eli Lilly's (LLY) CEO John Lechleiter on Q2 2014 Results - Earnings Call Transcript

OperatorLadies and gentlemen, thank you for standing by. Welcome to the Q 2014 earnings call. At this time, all participants are in a listen only mode. Later we will conduct a question-and-answer session. (Operator Instructions). As a reminder, this conference ... [Published Seeking Alpha - Jul 25 2014]
First reported Jul 23 2014 - Updated Jul 23 2014 - 1 reports

Gene marker may predict breast cancer response to tamoxifen

(HealthDay)—Researchers have identified genes that may help predict whether a patient with estrogen receptor (ER)-positive breast cancer is likely to benefit from tamoxifen therapy, according to a study published in the July 15 issue of Cancer Resear ... [Published Medical Xpress - Jul 23 2014]
First reported Jun 25 2014 - Updated Jun 25 2014 - 1 reports

Syndax Pharmaceuticals: An Interesting IPO Investment

Summary Entinostat breakthrough therapy designation helps to make investors confident in the Phase III trial. The upcoming IPO should provide the funds needed to advance the clinical trials. Syndax is poised to increase in share price as Entinostat ... [Published Seeking Alpha - Jun 25 2014]
First reported Jun 25 2014 - Updated Jun 25 2014 - 1 reports

A New Era in the Management of Advanced HER2-Positive Breast Cancer

By Karen Lisa Smith, MD, MPH, and Vered Stearns, MDJune 25, 2014, Volume 5, Issue 10Approximately 20% of all breast cancers are human epidermal growth factor receptor 2 (HER2)-positive. Prior to the era of HER2-targeted therapy, HER2-positive breast cancer ... [Published The ASCO Post - Jun 25 2014]
First reported Jun 24 2014 - Updated Jun 24 2014 - 1 reports

Mount Kisco Medical Group and Northern Westchester Hospital Now...

Cancer Treatment and Wellness Center is one of the first sites in the world to provide patients with access to leading edge breast cancer drug trial PALOMA-3. The Cancer Treatment and Wellness Center at Northern Westchester Hospital is now enrolling patients ... [Published PRWeb - Jun 24 2014]
First reported Jun 23 2014 - Updated Jun 23 2014 - 1 reports

Hydroxychloroquine for Tamoxifen Resistance in Breast Cancer

Reuters Health InformationBy Will Boggs MDJune 23, 2014NEW YORK (Reuters Health) - The antimalarial drug hydroxychloroquine overcomes breast cancer resistance to tamoxifen, according to preclinical studies of estrogen receptor-positive (ER+) mammary ... [Published Diabetes Care - Jun 23 2014]
First reported May 19 2014 - Updated May 19 2014 - 1 reports

Pfizer to submit palbociclib NDA with US FDA based on final results of PALOMA-1

Pfizer Inc. will submit a New Drug Application (NDA) with the United States Food and Drug Administration (FDA) for palbociclib, combined with letrozole, as first-line systemic treatment of post-menopausal women with estrogen receptor positive (ER+), human ... [Published PharmaBiz - May 19 2014]
First reported May 13 2014 - Updated May 13 2014 - 1 reports

Human medicines European public assessment report (EPAR): Faslodex, fulvestrant, Revision: 12, Authorised

Entities: fulvestrant, Faslodex
First reported Apr 07 2014 - Updated Apr 07 2014 - 1 reports

Pfizer’s novel CDK 4/6 inhibitor palbociclib plus letrozole significantly prolonged PFS in patients with advanced breast cancer

Pfizer Inc. announced detailed results from the PALOMA-1 study, a randomized phase 2 study of palbociclib (PD-0332991) in combination with letrozole. PALOMA-1 achieved its primary endpoint by significantly prolonging progression-free survival (PFS) compared ... [Published PharmaBiz - Apr 07 2014]
First reported Feb 13 2014 - Updated Feb 13 2014 - 1 reports

Fulvestrant 500 mg vs 250 mg in CONFIRM Trial

Related Biotechnology, Pharmaceutical and Healthcare NewsIn patients with locally advanced or metastatic estrogen receptor--positive breast cancer, which dosing improves the odds? Journal of the National Cancer InstituteOriginal Article: NEXT ARTICLE ... [Published BioPortfolio - Feb 13 2014]

Quotes

"Overall, our findings identify a gene signature as a candidate biomarker of response to tamoxifen in breast cancer" the authors write
"A well-planned chloroquine combination therapy may be effective in managing drug resistance, recurrence, or distant metastasis of breast cancers" Dr. Chang said
...Mace Rothenberg, senior vice president of Clinical Development and Medical Affairs and chief medical officer for Pfizer Oncology. "We are proud to be at the forefront of research and development with respect to this promising new class of investigational anticancer agents and have initiated a broad clinical development programme for palbociclib that includes breast and non-breast cancers.”"
...PLOS ONE is an international, peer-reviewed, open-access, online publication in which the results appear under the title "Development and validation of a gene expression score that  predicts response to fulvestrant in breast cancer patients." ]]>

More Content

All (17) | News (15) | Reports (0) | Blogs (1) | Audio/Video (0) | Fact Sheets (0) | Press Releases (1)
sort by: Date | Relevance
Eli Lilly's (LLY) CEO John Lechleiter on Q2 201... [Published Seeking Alpha - Jul 25 2014]
Gene marker may predict breast cancer response ... [Published Medical Xpress - Jul 23 2014]
Syndax Pharmaceuticals: An Interesting IPO Inve... [Published Seeking Alpha - Jun 25 2014]
A New Era in the Management of Advanced HER2-Po... [Published The ASCO Post - Jun 25 2014]
Mount Kisco Medical Group and Northern Westches... [Published PRWeb - Jun 24 2014]
Hydroxychloroquine for Tamoxifen Resistance in ... [Published Diabetes Care - Jun 23 2014]
Pfizer to submit palbociclib NDA with US FDA ba... [Published PharmaBiz - May 19 2014]
Human medicines European public assessment repo... [Published Pending EC decisions and European Public Assess ... - May 13 2014]
Pfizer’s novel CDK 4/6 inhibitor palbociclib pl... [Published PharmaBiz - Apr 07 2014]
Fulvestrant 500 mg vs 250 mg in CONFIRM Trial [Published BioPortfolio - Feb 13 2014]
MPI publishes data showing that MPI's product D... [Published GlobeNewswire: Advertising News - Feb 05 2014]
Higher Dose of Faslodex Effective in Advanced B... [Published BioPortfolio - Dec 30 2013]
2014 Pipeline Report: The Sprint to Value [Published Pharmaceutical Executive - Nov 08 2013]
Synta Announces Publication of First Patent App... [Published BioPortfolio - Oct 31 2013]
Pfizer Pharmaceutical Selects Southern Cancer C... [Published PRWeb - Oct 30 2013]
Estrogen receptors and methods of use [Published PharmCast - Oct 24 2013]
Lipid depot formulations [Published PharmCast - Oct 18 2013]
1
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
Human medicines European public assessment repo... [Published Pending EC decisions and European Public Assess ... - May 13 2014]
1

Press Releases

sort by: Date | Relevance
MPI publishes data showing that MPI's product D... [Published GlobeNewswire: Advertising News - Feb 05 2014]
1
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.